Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.7%

Share on StockTwits

Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) traded down 6.7% on Monday . The stock traded as low as $64.37 and last traded at $66.92. 4,669,446 shares changed hands during trading, an increase of 146% from the average session volume of 1,901,153 shares. The stock had previously closed at $71.70.

A number of equities analysts have recently commented on TNDM shares. BidaskClub raised shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 5th. Bank of America reissued a “neutral” rating and issued a $65.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, May 17th. ValuEngine raised shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 15th. Svb Leerink started coverage on shares of Tandem Diabetes Care in a research note on Monday, May 13th. They set an “outperform” rating and a $83.00 price target on the stock. Finally, Leerink Swann began coverage on shares of Tandem Diabetes Care in a research report on Monday, May 13th. They issued an “outperform” rating and a $83.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $68.13.

The company has a quick ratio of 2.13, a current ratio of 2.43 and a debt-to-equity ratio of 0.09. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -26.24 and a beta of 0.51.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. The company had revenue of $66.00 million during the quarter, compared to analyst estimates of $47.55 million. During the same quarter last year, the business earned ($1.82) EPS. The company’s revenue for the quarter was up 141.9% compared to the same quarter last year. Equities research analysts expect that Tandem Diabetes Care Inc will post -0.81 earnings per share for the current year.

In other Tandem Diabetes Care news, EVP Brian B. Hansen sold 10,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.00, for a total value of $720,000.00. Following the transaction, the executive vice president now directly owns 11,381 shares of the company’s stock, valued at approximately $819,432. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $62.60, for a total value of $125,200.00. Following the completion of the transaction, the executive vice president now directly owns 3,765 shares in the company, valued at $235,689. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,000 shares of company stock valued at $3,505,580. 6.90% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in TNDM. Wellington Management Group LLP acquired a new stake in Tandem Diabetes Care in the 1st quarter valued at $91,206,000. Columbus Circle Investors increased its holdings in Tandem Diabetes Care by 1,896.9% in the fourth quarter. Columbus Circle Investors now owns 848,842 shares of the medical device company’s stock valued at $32,231,000 after purchasing an additional 806,335 shares during the last quarter. Deutsche Bank AG increased its holdings in Tandem Diabetes Care by 130.1% in the fourth quarter. Deutsche Bank AG now owns 1,037,695 shares of the medical device company’s stock valued at $39,400,000 after purchasing an additional 586,684 shares during the last quarter. FMR LLC increased its holdings in Tandem Diabetes Care by 248.9% in the first quarter. FMR LLC now owns 705,789 shares of the medical device company’s stock valued at $44,818,000 after purchasing an additional 503,482 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Tandem Diabetes Care by 353.8% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 536,654 shares of the medical device company’s stock worth $34,078,000 after acquiring an additional 418,388 shares in the last quarter. 80.49% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.7%” was reported by Equities Focus and is the sole property of of Equities Focus. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.equitiesfocus.com/2019/06/10/tandem-diabetes-care-nasdaqtndm-trading-down-6-7.html.

About Tandem Diabetes Care (NASDAQ:TNDM)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.